Immunohistochemical localization of voltage-gated calcium channels in substantia nigra dopamine neurons.
The rhythmic firing of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc) is thought to be mediated by nifedipine-sensitive Ca(2+) channels, although an involvement of omega-conotoxin-sensitive Ca(2+) channels is also suggested. In an attempt to localize such Ca(2+) channels at both the regional and cellular levels, their expression and distribution patterns were immunohistochemically investigated in the rat SNc. The three distinct subtypes of voltage-gated Ca(2+) channels were tested: the class B N-type alpha 1 subunit (CNB1), the class C L-type alpha 1 subunit (CNC1) and the class D L-type alpha 1 subunit (CND1). A large number of SNc neurons showed intense immunoreactivity against CND1 and they were distributed throughout the entire extent. By contrast, many fewer neurons displayed less intense CNC1 immunoreactivity and many of them were located in the lateral aspect of the SNc. No immunoreactivity against CNB1 was detected in the SNc. Moreover, double immunofluorescence analysis in combination with tyrosine hydroxylase staining revealed that virtually all DA neurons were CND1-immunoreactive whereas many DA neurons especially in the medial SNc exhibited only faint or no immunoreactivity against CNC1. Both CNC1 and CND1 were expressed in cell bodies and proximal dendrites of SNc DA neurons, whilst their distal dendrites that penetrated into the substantia nigra pars reticulata expressed CND1 alone. Thus, the ubiquitously and intensely expressed class D alpha 1 subunit of L-type Ca(2+) channels that is sensitive to both nifedipine and omega-conotoxin may be responsible for the pacemaker activity of SNc DA neurons.
Takada
M
M
Tokyo Metropolitan Institute for Neuroscience, Fuchu, Tokyo 183-8526, Japan. takada@tmin.ac.jp
Kang
Y
Y
Imanishi
M
M
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000187:drug effects*; D020864:Calcium Channels, N-Type / Q000187:drug effects*; D004298:Dopamine / Q000032:analysis*; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D015640:Ion Channel Gating / Q000187:drug effects; D008297:Male; D009419:Nerve Tissue Proteins / Q000187:drug effects*; D009474:Neurons / Q000737:chemistry*; D009543:Nifedipine / Q000494:pharmacology; D021122:Protein Subunits; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000166:cytology*; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis; D020960:omega-Conotoxins / Q000494:pharmacology
D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D020864:Calcium Channels, N-Type; D009419:Nerve Tissue Proteins; D021122:Protein Subunits; D020960:omega-Conotoxins; D014446:Tyrosine 3-Monooxygenase; D009543:Nifedipine; D004298:Dopamine